Lesley Fallowfield, Ivonne Solis-Trapala, Alison Jones , Jane Barrett, Carolyn Langridge, Valerie Jenkins
British Journal of Healthcare Management, Vol. 17, Iss. 5, 06 May 2011, pp 206
- 212
Funding expensive new cancer therapies is increasingly problematic for healthcare systems worldwide. In this study wthe authors report UK clinicians' views and experiences when discussing expensive anti-cancer drugs with patients. A study-specific survey was emailed to members of relevant professional oncology organisations between April and August 2010: 368 clinicians responded. During the previous 12 months, 71% had made exceptional/individual funding requests; few were successful. Only 9% of clinicians discussed expensive drugs with all patients, 75% with 'some' and 16% with 'none'. Among those who told 'some', 81% (224/276) did so only if convinced of clinical benefit, 72% only if patients initiated the subject, and 55%, if relatives did. Clinicians treating both privately funded and NHS patients (43%) were three times more likely to discuss expensive treatments (p<0.001) than those working only within the NHS. Clinicians' reporting of patients' and relatives' reactions to such discussions was 'understanding' (63%, 45%), 'distress' (40%, 41%) and 'indignation' (24%, 38%). A majority of clinicians (98%) had received no guidance on conducting such discussions and 76% wanted training. This survey clearly demonstrated that few clinicians discuss expensive anti-cancer treatments with their patients and welcome access to a training programme to assist them.
To view this article
You cannot access this article because you do not have a valid subscription. Please use the options below to create a subscription. If you have any queries about your account please contact our subscriptions department or telephone free 0800 137201 (UK callers only) or +44 (0)1722 716997 for callers outside the UK.
